TargetBeta
TTR
transthyretin · also HsT2651, CTS, PALB, CTS1 · Gla domain containing
4 programs in company-led studies act on TTR, from 3 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| acoramidisrule | BridgeBio | phase 4 | 156 running | – | ChEMBL |
| tafamidisrule | Pfizer | phase 4 | 290 running | – | ChEMBL |
| coramitug | Novo Nordisk | phase 3 | 32 running | – | a judged reading |
| coramitug | Novo Nordisk | phase 1 | 21 running | – | a judged reading |
Conditions their studies are in
- Amyloidosis, 3 programs
- Amyloid Neuropathies, Familial, 2 programs
- Amyloidosis, Hereditary, Transthyretin-Related, 1 program
- Cardiomyopathies, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 30, 2027coramitug · Novo Nordisk · phase 1 · NCT07448623
- Sep 17, 2027acoramidis · BridgeBio · phase 4 · NCT07298044
- Feb 29, 2028coramitug · Novo Nordisk · phase 3 · NCT06260709
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.